Market Overview

Celgene Announces EC Approval for ABRAXANE Plus Gemcitabine for Treatment of Metastatic Pancreatic Cancer


Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation (NASDAQ: CELG), today announced that the European Commission
(EC) has granted approval for ABRAXANE (paclitaxel formulated as albumin
bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine
for first-line treatment of adult patients with metastatic
adenocarcinoma of the pancreas, or metastatic pancreatic cancer.1

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (CELG)

View Comments and Join the Discussion!

Partner Center